Royal Bank of Canada assumed coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $55.00 target price on the biotechnology company’s stock.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Aimmune Therapeutics from a buy rating to a hold rating in a report on Wednesday, December 6th. Credit Suisse Group raised their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an outperform rating in a report on Monday, October 23rd. Roth Capital lifted their price objective on Aimmune Therapeutics from $60.00 to $75.00 and gave the company a buy rating in a report on Wednesday, January 31st. Wedbush reiterated an outperform rating and set a $70.00 price objective (up previously from $42.00) on shares of Aimmune Therapeutics in a report on Monday, October 23rd. Finally, BidaskClub cut Aimmune Therapeutics from a buy rating to a hold rating in a report on Saturday, December 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Aimmune Therapeutics has an average rating of Buy and a consensus price target of $57.25.

Aimmune Therapeutics (AIMT) opened at $38.68 on Wednesday. Aimmune Therapeutics has a 1-year low of $15.97 and a 1-year high of $40.65.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. research analysts predict that Aimmune Therapeutics will post -2.51 EPS for the current year.

In other news, insider Douglas T. Sheehy sold 1,648 shares of Aimmune Therapeutics stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $37.33, for a total transaction of $61,519.84. Following the transaction, the insider now owns 1,648 shares in the company, valued at approximately $61,519.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Douglas T. Sheehy sold 1,906 shares of Aimmune Therapeutics stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $38.66, for a total value of $73,685.96. Following the transaction, the insider now owns 1,906 shares in the company, valued at approximately $73,685.96. The disclosure for this sale can be found here. Insiders have sold a total of 134,294 shares of company stock worth $5,097,144 in the last quarter. 24.56% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Hamilton Lane Advisors LLC bought a new position in shares of Aimmune Therapeutics during the 4th quarter valued at about $2,982,000. Point72 Asset Management L.P. lifted its stake in Aimmune Therapeutics by 10.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock valued at $27,222,000 after acquiring an additional 101,855 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Aimmune Therapeutics in the 2nd quarter valued at approximately $442,000. Goldman Sachs Group Inc. lifted its stake in Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock valued at $4,675,000 after acquiring an additional 132,603 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Aimmune Therapeutics by 16.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock valued at $2,700,000 after acquiring an additional 19,016 shares in the last quarter. Institutional investors and hedge funds own 73.54% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dailypolitical.com/2018/02/10/aimmune-therapeutics-aimt-now-covered-by-royal-bank-of-canada.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.